These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24909571)

  • 21. The link between VLA-4 and JC virus reactivation.
    Monaco MC; Major EO
    Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the management of PML: focus on natalizumab.
    Fox R
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR; Stüve O
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding.
    Maginnis MS; Ströh LJ; Gee GV; O'Hara BA; Derdowski A; Stehle T; Atwood WJ
    mBio; 2013 Jun; 4(3):e00247-13. PubMed ID: 23760462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
    Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
    Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F; Newsome SD; Viscidi R
    Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
    J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
    Rossi F; Prosperini L; De Rossi N; Capra R; Rivanera D; Li X; Cinque P; Passeri L; Pozzilli C; Viscidi R
    Viral Immunol; 2017 Oct; 30(8):622-626. PubMed ID: 28836899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human iPS cell-derived astrocytes support efficient replication of progressive multifocal leukoencephalopathy-type JC polyomavirus.
    Shimbo E; Nukuzuma S; Tagawa YI
    Biochem Biophys Res Commun; 2020 Dec; 533(4):983-987. PubMed ID: 33008586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
    Warnke C; Adams O; Gold R; Hartung HP; Hohlfeld R; Wiendl H; Kieseier BC
    Nervenarzt; 2011 Apr; 82(4):475-80. PubMed ID: 21240604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC; Hecht EM
    Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL; Chitnis T; Healy BC
    Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Schneider-Hohendorf T; Schulte-Mecklenbeck A; Ostkamp P; Janoschka C; Pawlitzki M; Luessi F; Zipp F; Meuth SG; Klotz L; Wiendl H; Gross CC; Schwab N
    Mult Scler; 2021 Sep; 27(10):1491-1496. PubMed ID: 33150829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JCPyV VP1 Mutations in Progressive MultifocalLeukoencephalopathy: Altering Tropismor Mediating Immune Evasion?
    Lauver MD; Lukacher AE
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33053912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.